Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:149 |
|---|---|
| Enthalten in: |
Annales de dermatologie et de venereologie - 149(2022), 2 vom: 15. Juni, Seite 142-145 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pottier, C [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 08.06.2022 Date Revised 09.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annder.2022.01.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33721994X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33721994X | ||
| 003 | DE-627 | ||
| 005 | 20231225233921.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annder.2022.01.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1124.xml |
| 035 | |a (DE-627)NLM33721994X | ||
| 035 | |a (NLM)35190214 | ||
| 035 | |a (PII)S0151-9638(22)00002-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pottier, C |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Myasthenia gravis induced by pembrolizumab in a patient with metastatic Merkel cell carcinoma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.06.2022 | ||
| 500 | |a Date Revised 09.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Immune adverse event | |
| 650 | 4 | |a Immune checkpoint inhibitors | |
| 650 | 4 | |a Myasthenia gravis | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 700 | 1 | |a El Habnouni, C |e verfasserin |4 aut | |
| 700 | 1 | |a Kervarrec, T |e verfasserin |4 aut | |
| 700 | 1 | |a Beltran, S |e verfasserin |4 aut | |
| 700 | 1 | |a Samimi, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annales de dermatologie et de venereologie |d 1986 |g 149(2022), 2 vom: 15. Juni, Seite 142-145 |w (DE-627)NLM000154113 |x 0151-9638 |7 nnns |
| 773 | 1 | 8 | |g volume:149 |g year:2022 |g number:2 |g day:15 |g month:06 |g pages:142-145 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annder.2022.01.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 149 |j 2022 |e 2 |b 15 |c 06 |h 142-145 | ||